- Home
- SWVL vs LTRN Comparison
SWVL vs LTRN Comparison
Compare SWVL & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWVL
- LTRN
- Stock Information
- Founded
- SWVL 2017
- LTRN 2013
- Country
- SWVL United Arab Emirates
- LTRN United States
- Employees
- SWVL N/A
- LTRN N/A
- Industry
- SWVL Business Services
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- SWVL Consumer Discretionary
- LTRN Health Care
- Exchange
- SWVL Nasdaq
- LTRN Nasdaq
- Market Cap
- SWVL 37.6M
- LTRN 36.0M
- IPO Year
- SWVL N/A
- LTRN 2020
- Fundamental
- Price
- SWVL $3.47
- LTRN $3.81
- Analyst Decision
- SWVL
- LTRN Strong Buy
- Analyst Count
- SWVL 0
- LTRN 1
- Target Price
- SWVL N/A
- LTRN $25.00
- AVG Volume (30 Days)
- SWVL 17.2K
- LTRN 73.6K
- Earning Date
- SWVL 09-08-2025
- LTRN 11-06-2025
- Dividend Yield
- SWVL N/A
- LTRN N/A
- EPS Growth
- SWVL N/A
- LTRN N/A
- EPS
- SWVL N/A
- LTRN N/A
- Revenue
- SWVL $19,329,423.00
- LTRN N/A
- Revenue This Year
- SWVL N/A
- LTRN N/A
- Revenue Next Year
- SWVL N/A
- LTRN N/A
- P/E Ratio
- SWVL N/A
- LTRN N/A
- Revenue Growth
- SWVL N/A
- LTRN N/A
- 52 Week Low
- SWVL $2.40
- LTRN $2.55
- 52 Week High
- SWVL $7.50
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- SWVL 41.69
- LTRN 39.37
- Support Level
- SWVL $3.33
- LTRN $3.74
- Resistance Level
- SWVL $4.01
- LTRN $4.26
- Average True Range (ATR)
- SWVL 0.33
- LTRN 0.31
- MACD
- SWVL 0.02
- LTRN -0.06
- Stochastic Oscillator
- SWVL 34.94
- LTRN 7.59
About SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.